Meridian Bioscience Announces the Launch of TruQuick(TM) Rapid Tests for Asia Pacific
(Thomson Reuters ONE) -
CINCINNATI, Feb. 03, 2017 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc.
(NASDAQ:VIVO) today announced the launch of TruQuick(TM), a comprehensive point-
of-care product menu of rapid tests for the diagnosis of tropical, infectious,
sexually transmitted, respiratory, gastrointestinal, cancer, and cardiac
diseases. This product menu will enable Meridian to rapidly expand its product
portfolio of high value rapid tests for its commercial operations in Asia
Pacific and other emerging markets around the world.
TruQuick(TM) is a qualitative lateral flow chromatographic immunoassay menu of
over 60 products. TruQuick(TM) rapid tests can aid in the diagnosis of
infectious pathogens and other important acute diseases in 10 to 20 minutes with
high levels of accuracy and speed to results. Meridian understands the clinical
testing requirements in Asia and other emerging markets for speed, sensitivity,
specificity, and breadth of product line.
Lourdes Weltzien, Ph.D., President of Meridian Asia Pacific commented, "We are
excited to launch the new TruQuick(TM) brand of rapid tests for the rapidly
growing point-of-care market in the Asia Pacific region. As for other regions of
the world, Meridian will quickly introduce the TruQuick(TM) brand of products
based on regional demands and registration priorities."
Richard L. Eberly, President, Chief Commercial Officer, stated, "One of
Meridian's key strategies over the past few years has been to expand our global
commercial operations in emerging markets around the world. Meridian has
expanded operations in China, Singapore, Australia, Africa, and South America.
The product portfolio for these emerging markets is rapidly expanding. We are
delighted to add the TruQuick(TM) brand of rapid point-of-care products to our
commercial channels in these important markets."
About Meridian Bioscience, Inc.
Meridian is a fully integrated life science company that develops, manufactures,
markets and distributes a broad range of innovative diagnostic test kits, rare
reagents, specialty biologicals and components. Utilizing a variety of methods,
our diagnostic tests provide accuracy, simplicity and speed in the early
diagnosis and treatment of common medical conditions, such as infections and
lead poisoning. Meridian's diagnostic products are used outside of the human
body and require little or no special equipment. The Company's diagnostic
products are designed to enhance patient well-being while reducing the total
outcome costs of health care. Meridian has strong market positions in the areas
of gastrointestinal and upper respiratory infections and blood lead level
testing. In addition, Meridian is a supplier of rare reagents, specialty
biologicals and components used by organizations in the life science and agribio
industries engaged in research and by companies as components in the manufacture
of diagnostics. The Company markets its products and technologies to hospitals,
reference laboratories, research centers, diagnostics manufacturers and agribio
companies in more than 70 countries around the world. The Company's shares are
traded on the NASDAQ Global Select Market, symbol VIVO. Meridian's website
address is www.meridianbioscience.com.
CONTACT:
Richard L. Eberly
President, Chief Commercial Officer
Meridian Bioscience, Inc.
Phone: 513.271.3700
rick.eberly(at)meridianbioscience.com
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Meridian Bioscience, Inc. via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 03.02.2017 - 17:10 Uhr
Sprache: Deutsch
News-ID 521903
Anzahl Zeichen: 4123
contact information:
Town:
Cincinnati
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 258 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Meridian Bioscience Announces the Launch of TruQuick(TM) Rapid Tests for Asia Pacific"
steht unter der journalistisch-redaktionellen Verantwortung von
Meridian Bioscience, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
